---

May 5, 2025

On May 5, 2025, President Donald Trump took significant steps to shape national policy by signing a new executive order and issuing three presidential proclamations. These actions, announced around 3:45 PM MDT, address critical issues ranging from biosecurity to public awareness campaigns. The executive order, titled “Improving the Safety and Security of Biological Research,” targets risky gain-of-function research, while the proclamations designate National Small Business Week, National Hurricane Preparedness Week, and National Mental Health Awareness Month for 2025. Reports also suggest a second executive order on rebuilding U.S. prescription drug manufacturing, though details remain limited. This article explores these developments, their implications, and what they mean for the nation.

Executive Order: Improving the Safety and Security of Research

A Bold Move on Biosecurity

The centerpiece of President Trump’s actions on May 5, 2025, is an executive order aimed at enhancing the safety and security of biological research. Titled “Improving the Safety and Security of Biological Research,” this order addresses concerns about gain-of-function research—experiments that modify pathogens to increase their transmissibility or virulence, often linked to potential pandemic risks. The order specifically bans federal funding for such research in countries deemed to lack proper oversight, including China and Iran, and introduces stringent measures to safeguard public health and national security.

Key provisions of the executive order include:

• Funding Restrictions: The order prohibits all current and future federal funding for gain-of-function research in “countries of concern” and foreign nations without robust regulatory frameworks. This move responds to past controversies, such as the $1.4 million funneled through EcoHealth Alliance to the Wuhan Institute of Virology from 2014 to 2021 for bat coronavirus research, as noted in White House statements.
• Research Pause: All research involving infectious pathogens and toxins is temporarily halted until a new policy is developed. This policy, to be crafted by the Director of the Office of Science and Technology Policy and the national security adviser, will include enforcement mechanisms and mandatory reporting to ensure compliance.
• Agency Empowerment: Federal agencies, including the National Institutes of Health (NIH), are tasked with identifying and terminating funding for biological research that could harm public health or national security. This includes reviewing ongoing projects to mitigate risks.
• Historical Context: The order builds on previous biosecurity efforts, such as President Biden’s 2022 ban on certain gain-of-function research (Public Law 117-328). It also addresses oversight gaps highlighted in a Pentagon report, which cited significant limitations in tracking research funding.

The White House emphasized that this order aims to prevent lab-related incidents that could trigger outbreaks, drawing parallels to debates about the origins of COVID-19. While the Office of the Director of National Intelligence’s 2021 report found no definitive link between the Wuhan Institute and the pandemic, the administration argues that the risks of such research outweigh potential benefits in under-regulated environments.

Implications

This executive order has far-reaching implications for global health research and U.S. policy:

• Research Landscape: By restricting funding, the U.S. may reduce its involvement in international collaborations, potentially shifting research to domestic or allied institutions with stricter oversight.
• National Security: Enhanced scrutiny of biological research aligns with broader efforts to protect against bioterrorism and accidental outbreaks, reinforcing the administration’s “America First” approach.
• Scientific Community: Researchers may face delays or cancellations of projects involving pathogens, prompting debates about balancing safety with scientific progress.
• International Relations: The ban on funding in countries like China could strain diplomatic ties, especially amid ongoing tensions over trade and technology.

As of May 5, 2025, the order’s full text is not yet published due to standard delays in the Federal Register, but updates are expected soon on the White House Presidential Actions page.

Potential Second Executive Order: Rebuilding Prescription Drug Manufacturing

A Push for Domestic Production

Emerging reports, suggest that President Trump also signed a second executive order on May 5, 2025, focused on rebuilding U.S. prescription drug manufacturing, including key ingredients. While official confirmation is pending, sources like Benny Johnson and Autism Capital indicate this order aims to reduce reliance on foreign supply chains, particularly from countries like China and India, which dominate global pharmaceutical production.

Though details are scarce, the order likely includes:

• Incentives for Domestic Manufacturing: Tax breaks, grants, or regulatory streamlining to encourage U.S. companies to produce drugs and active pharmaceutical ingredients (APIs) domestically.
• Supply Chain Resilience: Measures to address vulnerabilities exposed during the COVID-19 pandemic, when shortages of critical drugs highlighted dependence on foreign suppliers.
• Alignment with Health Policy: This action complements earlier 2025 efforts, such as the April 15 executive order on lowering drug prices and the February 12 establishment of the President’s Make America Healthy Again Commission (EO 14212).

Why It Matters

If confirmed, this order could transform the U.S. pharmaceutical industry:

• Economic Impact: Revitalizing domestic manufacturing could create jobs and boost local economies, aligning with Trump’s economic agenda.
• Health Security: Reducing reliance on foreign drugs enhances national resilience against global disruptions, from pandemics to geopolitical conflicts.
• Challenges: Scaling up domestic production faces hurdles, including high costs, regulatory barriers, and competition from established foreign manufacturers.

The lack of official documentation as of 4:09 PM MDT on May 5, 2025, suggests caution in interpreting these reports. Readers should monitor the Federal Register for updates.

Presidential Proclamations: Raising Awareness in 2025

In addition to the executive order(s), President Trump issued three proclamations on May 5, 2025, recognizing key observances: National Small Business Week, National Hurricane Preparedness Week, and National Mental Health Awareness Month. These proclamations, authorized under U.S. law, aim to engage the public in economic, safety, and health initiatives.

National Small Business Week, 2025

This proclamation celebrates the vital role of small businesses, which employ nearly half of U.S. workers and drive innovation. Issued on May 5, 2025, it calls for “appropriate ceremonies and activities” to honor entrepreneurs. Organized by the Small Business Administration (SBA), National Small Business Week typically includes events like workshops and awards ceremonies. While the exact text is not yet available, it follows the tradition of past proclamations, emphasizing economic growth and resilience.

Impact: The proclamation reinforces the administration’s pro-business stance, potentially amplifying policies like tax cuts or deregulation. It resonates with small business owners navigating post-pandemic recovery and inflation challenges.

National Hurricane Preparedness Week, 2025

Aimed at preparing Americans for hurricane season, this proclamation encourages emergency planning and resilience. Issued on May 5, 2025, it likely urges citizens to create disaster kits, stay informed about weather forecasts, and strengthen community defenses. Supported by FEMA and NOAA, the week promotes proactive measures amid rising extreme weather events driven by climate change.

Impact: By raising awareness, the proclamation supports federal and local efforts to reduce hurricane-related losses, which cost billions annually. It complements broader disaster preparedness policies.

National Mental Health Awareness Month, 2025

This proclamation, also issued on May 5, 2025, highlights the importance of mental health, a growing national priority. It calls for public engagement to reduce stigma and improve access to services, reflecting data showing one in five U.S. adults live with mental illness. The proclamation aligns with the administration’s health initiatives, including the Make America Healthy Again Commission.

Impact: By spotlighting mental health, the proclamation fosters dialogue and may bolster funding or programs for mental health care, addressing disparities exacerbated by recent crises.

Context and Broader Significance

These actions come amid a busy start to President Trump’s second term, with 143 executive orders signed by May 2, 2025, according to Ballotpedia. The biological research order, likely EO 14290 or higher, underscores a focus on biosecurity and health policy, while the potential drug manufacturing order aligns with economic nationalism. The proclamations, though symbolic, reinforce priorities in economic growth, disaster readiness, and public health.

Challenges and Uncertainties

• Publication Delays: The Federal Register and White House websites typically lag by 1–3 days, meaning full texts for the May 5 actions are not yet available. This delay is standard, as seen with earlier 2025 orders.
• Drug Manufacturing Order: Limited corroboration beyond social media posts raises questions about its scope and timing. Official confirmation is needed to clarify its provisions.
• Implementation: The biological research order faces logistical challenges, including coordinating agency reviews and balancing scientific freedom with safety. The drug manufacturing order, if real, requires significant investment and regulatory reform.

What to Watch For

• Official Texts: Check the White House and Federal Register for the executive order(s) and proclamation texts, expected within days.
• Policy Rollout: Monitor agency announcements, such as from the NIH or Department of Health and Human Services, for details on implementing the biological research restrictions.
• Public Reaction: The scientific community, pharmaceutical industry, and public may respond variably, with potential debates over research freedom, economic costs, and health priorities.

Conclusion

President Trump’s actions on May 5, 2025, reflect a multifaceted approach to governance, tackling biosecurity, economic resilience, and public awareness. The executive order on biological research sets a bold precedent for regulating high-risk science, while the reported drug manufacturing order, if confirmed, could reshape the pharmaceutical landscape. The three proclamations—National Small Business Week, National Hurricane Preparedness Week, and National Mental Health Awareness Month—engage Americans in critical issues, from economic vitality to health and safety. As these policies unfold, they will shape debates about America’s future in a complex global landscape.

For the latest updates, visit WhiteHouse.gov or follow Ashes on Air for real-time analysis. Stay informed, stay engaged, and let’s navigate these changes together.

---

Sources: New York Post, Ballotpedia, Federal Register, White House, X posts by Benny Johnson and Autism Capital, Disabled World.